This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumors. Nature. 2000; 406:747–752.PerouCMSørlieTEisenMBvan de RijnMJeffreySSReesCAMolecular portrait of human breast tumors200040674775210.1038/3502109310963602Search in Google Scholar
[Guideline] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 1.2016. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Version 3.2018 – October 25, 2018; Accessed: December 7, 2018.National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Version 3.2018 – October 25, 2018; Accessed: December 7, 2018.Search in Google Scholar
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013: 31, 3997–4013.WolffACHammondMEHicksDGDowsettMMcShaneLMAllisonKHRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update2013313997401310.1200/JCO.2013.50.998424101045Search in Google Scholar
Portha H, Jankowski C, Cortet M, Desmoulins I, Martin E, Lorgis V, Arnould L, Coutant C. [Nonmetastatic triple-negative breast cancer in 2016: Definitions and management]. Gynecol Obstet Fertil. 2016 Sep;44(9):492–504.PorthaHJankowskiCCortetMDesmoulinsIMartinELorgisVArnouldLCoutantC[Nonmetastatic triple-negative breast cancer in 2016: Definitions and management]2016Sep44949250410.1016/j.gyobfe.2016.06.01427451066Search in Google Scholar
Prat A, Adamo B, Cheang MC. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18:123–33.PratAAdamoBCheangMCMolecular characterization of basal-like and non-basal-like triple-negative breast cancer2013181233310.1634/theoncologist.2012-0397357959523404817Search in Google Scholar
Chandra D, Suresh P, Sinha R, Azam S, Batra U, Talwar V, Kumar K, Mehta A. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India. Asian Pac J Cancer Prev. 2016; 17:2995–9.ChandraDSureshPSinhaRAzamSBatraUTalwarVKumarKMehtaAEight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India20161729959Search in Google Scholar
Jia Jin, Yu Gao, Jian Zhang, Leiping Wang, Biyun Wang, Jun Cao, Zhimin Shao, Zhonghua Wang. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 2018; 18: 446.JinJiaGaoYuZhangJianWangLeipingWangBiyunCaoJunShaoZhiminWangZhonghuaIncidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer20181844610.1186/s12885-018-4371-0590925429673325Search in Google Scholar
Weigelt B, Ng CK, Shen R, Popova T, Schizas M, Natrajan R, et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol. 2015; 28:340–351.WeigeltBNgCKShenRPopovaTSchizasMNatrajanRMetastatic breast carcinomas display genomic and transcriptomic heterogeneity20152834035110.1038/modpathol.2014.142452323925412848Search in Google Scholar
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Invest. 2011; 121:2750–67.LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYIdentification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies201112127506710.1172/JCI45014312743521633166Search in Google Scholar
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014; 232:142–150.LehmannBDPietenpolJAIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes201423214215010.1002/path.4280409003124114677Search in Google Scholar
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015; 21:1688–1698.BursteinMDTsimelzonAPoageGMCovingtonKRContrerasAFuquaSAComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer2015211688169810.1158/1078-0432.CCR-14-0432436288225208879Search in Google Scholar
Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43.JézéquelPLoussouarnDGuérin-CharbonnelCCampionLVanierAGouraudWGene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response2015174310.1186/s13058-015-0550-y438940825887482Search in Google Scholar
Valentin MD, da Silva SD, Privat M, Molecular insights on basal-like breast cancer. Breast Cancer Res Treat. 2012; 134(1):21–30.ValentinMDda SilvaSDPrivatMMolecular insights on basal-like breast cancer20121341213010.1007/s10549-011-1934-zSearch in Google Scholar
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902–1909.IsakoffSJMayerELHeLTrainaTACareyLAKragKJTBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer2015331902190910.1200/JCO.2014.57.6660Search in Google Scholar
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011 ; 15;10:1563–70.JiangZJonesRLiuJCDengTRobinsonTChungPERB1 and p53 at the crossroad of EMT and triple-negative breast cancer2011151015637010.4161/cc.10.10.15703Search in Google Scholar
Pfister K, Pipka JL, Chiang C, Liu Y, Clark RA, Keller R, et al. Todd Stukenberg. Identification of Drivers of Aneuploidy in Breast Tumors Cell Rep. 2018 ; 29; 23: 2758–2769.PfisterKPipkaJLChiangCLiuYClarkRAKellerRTodd Stukenberg201829232758276910.1016/j.celrep.2018.04.102Search in Google Scholar
Watkins JA, Irshad S, Grigoriadis A. Genomic scars as bio markers bio markers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014; 16:211.WatkinsJAIrshadSGrigoriadisAGenomic scars as bio markers bio markers of homologous recombination deficiency and drug response in breast and ovarian cancers20141621110.1186/bcr3670Search in Google Scholar
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–533RobsonMImSASenkusEXuBDomchekSMMasudaNOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation201737752353310.1056/NEJMoa1706450Search in Google Scholar
Turner NC, Telli ML, Rugo HS, Mailliez M, J Ettl J, Grischke E-M, et al. Phase II ABRAZO: Talazoparib in gBRCA1/2 Mutation–Positive MBC.(Abstract 1007). Presented Jul 10 2017 ASCO Annual Meeting.TurnerNCTelliMLRugoHSMailliezMJ EttlJGrischkeE-MPresented Jul 10 2017 ASCO Annual Meeting10.1200/JCO.2017.35.15_suppl.1007Search in Google Scholar
Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a ran domised phase 2 trial. Lancet Oncol 2014; 15:747–56.Von MinckwitzGSchneeweissALoiblSSalatCDenkertCRezaiMBlohmerJUNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a ran domised phase 2 trial2014157475610.1016/S1470-2045(14)70160-3Search in Google Scholar
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru bicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13–21.SikovWMBerryDAPerouCMSinghBCirrincioneCTTolaneySMImpact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru bicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)201533132110.1200/JCO.2014.57.0572Search in Google Scholar
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16:436–46.HuXCZhangJXuBHCaiLRagazJWangZHCisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial2015164364610.1016/S1470-2045(15)70064-1Search in Google Scholar
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 3; 17:63.YardleyDABrufskyAColemanREContePFCortesJGlückSErratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial2016Feb3176310.1186/s13063-016-1195-6473938926841937Search in Google Scholar
Tutt A, Ellis P, Kilburn L, Cheang M, Bliss J, Dowsett M, Flanagan J. et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. (Abstract S3-01). Presented at December 11, 2014. SABCS 2014.TuttAEllisPKilburnLCheangMBlissJDowsettMFlanaganJPresented atDecember 11, 2014SABCS 2014Search in Google Scholar
Choi JE, Kang SH, Lee SJ and Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015; 22: 82–89.ChoiJEKangSHLeeSJBaeYKAndrogen receptor expression predicts decreased survival in early stage triple-negative breast cancer201522828910.1245/s10434-014-3984-z25145503Search in Google Scholar
McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer sub type. Ann Surg Oncol 2014; 21: 361–367.McGhanLJMcCulloughAEProtheroeCADueckACLeeJJNunez-NaterasRAndrogen receptor-positive triple negative breast cancer: a unique breast cancer sub type20142136136710.1245/s10434-013-3260-724046116Search in Google Scholar
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19:5505–12.GucalpATolaneySIsakoffSJIngleJNLiuMCCareyLAPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer20131955051210.1158/1078-0432.CCR-12-3327408664323965901Search in Google Scholar
Traina TA, Miller K, Yardley DA, O’Shaughnessy J, Cortes J, Gradishar W, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol 2015; 33: S1003.TrainaTAMillerKYardleyDAO’ShaughnessyJCortesJGradisharWResults from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)201533S100310.1200/jco.2015.33.15_suppl.1003Search in Google Scholar
Adams S, Schmid P, Rugo HS, Loi S, Toppmeyer D, Awada A, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B (Abstract 1008.) Presented June 3, 2017 ASCO Annual Meeting.AdamsSSchmidPRugoHSLoiSToppmeyerDAwadaAPresentedJune 3, 2017ASCO Annual Meeting10.1200/JCO.2017.35.15_suppl.1088Search in Google Scholar
Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015;7:309–16.DalgleishAGRationale for combining immunotherapy with chemotherapy201573091610.2217/imt.14.11125804482Search in Google Scholar
Kok M, Horlings HM, Vijver K. Russell N, Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial (Abstract LBA14) Presented Mar 31, 2017 ESMO Annual Meeting.KokMHorlingsHMVijverKRussellNPresentedMar 31, 2017ESMO Annual Meeting10.1093/annonc/mdx440.006Search in Google Scholar
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, et al; Atezolizumab and NabPaclitaxel in Advanced Triple Negative Breast Cancer. N Engl J Med. 2018;379:2108–2121.SchmidPAdamsSRugoHSSchneeweissABarriosCHAtezolizumab and NabPaclitaxel in Advanced Triple Negative Breast Cancer20183792108212110.1056/NEJMoa180961530345906Search in Google Scholar
Yam C, Mani SA, Moulder SL. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist. 2017; 22:1086–1093.YamCManiSAMoulderSLTargeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field2017221086109310.1634/theoncologist.2017-0095559919228559413Search in Google Scholar
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615–23.CareyLARugoHSMarcomPKMayerELEstevaFJMaCXTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer20123026152310.1200/JCO.2010.34.5579341327522665533Search in Google Scholar
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92.BaselgaJGómezPGreilRBragaSClimentMAWardleyAMRandomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer20133125869210.1200/JCO.2012.46.2408570519123733761Search in Google Scholar
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 12; 377:914–23.CortesJO’ShaughnessyJLoeschDBlumJLVahdatLTPetrakovaKEMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study2011123779142310.1016/S0140-6736(11)60070-6Search in Google Scholar
Berkey CS, Rosner B, Tamimi RM, Willett WC, Hickey M, Toriola A, et al. Body size from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 2017;162:139–149.BerkeyCSRosnerBTamimiRMWillettWCHickeyMToriolaABody size from birth through adolescence in relation to risk of benign breast disease in young women201716213914910.1007/s10549-016-4084-5529008928062981Search in Google Scholar
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al, Refinement of Triple Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11: e0157368.LehmannBDJovanovićBChenXEstradaMVJohnsonKNShyrYRefinement of Triple Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection201611e015736810.1371/journal.pone.0157368491105127310713Search in Google Scholar
Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018; 7; 10:2475–2488.ZhuYZhaoFLiZYuJCurrent landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors20187102475248810.2147/CMAR.S167400608611030122997Search in Google Scholar
Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015; 26: 1904–1910.DiérasVCamponeMYardleyDARomieuGValeroVIsakoffSJRandomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer2015261904191010.1093/annonc/mdv26326202594Search in Google Scholar
Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, et al. Breast cancer molecular subtypes: from TNBC to QNBC Am J Cancer Res 2016;6:1864–1872.HonJDSinghBSahinADuGWangJWangVY2016618641872Search in Google Scholar
Barton VN, D’Amato NC, Gordon MA. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer 2015; 6: 206–213.BartonVND’AmatoNCGordonMAAndrogen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease2015620621310.1007/s12672-015-0232-3689749926201402Search in Google Scholar
Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl JMed 2008; 358:1409–1411.PaikSKimCWolmarkNHER2 status and benefit from adjuvant trastuzumab in breast cancer20083581409141110.1056/NEJMc080144018367751Search in Google Scholar
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 2016; 27:1241–1248.MittendorfEAArdavanisASymanowskiJMurrayJLShumwayNMLittonJKPrimary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence2016271241124810.1093/annonc/mdw150492231627029708Search in Google Scholar
Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009; 15:842–4.PratAPerouCMMammary development meets cancer genomics200915842410.1038/nm0809-84219661985Search in Google Scholar